Evercore Out Positive On Heron Therapeutics, Gives Bullish Scenario Of $150/Share If HTX-011 Is Rapidly Adopted By Hospital Pharmacies & Committees, Is Able To Expand Into Low Vol. Procedures, And Is Able To Reduce Hospitalization Duration Post-Procedures